Molecular Partners Reports Q3 2025 Financial Results And Clinical Progress, With Dll3-Targeting Radio-Darpin Mp0712 Phase 1 Launch Expected In 2025
Refinitiv1分未満で読めます
Molecular Partners AG MOLN:
MOLECULAR PARTNERS REPORTS Q3 2025 FINANCIAL RESULTS AND CLINICAL PROGRESS, WITH DLL3-TARGETING RADIO-DARPIN MP0712 PHASE 1 LAUNCH EXPECTED IN 2025
ログイン、もしくは永年無料のアカウントを作成して、このニュースを読みましょう